针对CD8+T细胞的IL2促进了强大的T细胞反应和强大的抗瘤免疫力
Kelly D Moynihan1, Manu P Kumar1, Hussein Sultan2
1Asher Biotherapeutics, Inc., South San Francisco, California.
Cancer discovery
|April 2, 2024
概括
向 CD8+ T 细胞准介素-2 (IL2) 增强了抗瘤活性,同时降低了毒性. 这种新的方法,以AB248为例,可以选择性地扩展CD8+T细胞,提高癌症治疗潜力.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 干白素-2 (IL2) 对各种细胞类型具有性作用,影响抗瘤活性和免疫抑制和毒性等不良影响.
- 目前的IL2疗法面临着因其广泛的信号传递而最大限度地提高治疗效益,同时最大限度地减少副作用的挑战.
- 专门针对IL2的CD8+T细胞,对于抗瘤免疫至关重要,是增强治疗指数的一个有希望的策略.
研究的目的:
- 研究向IL2到CD8+T细胞的潜力,以提高其治疗疗效和安全性.
- 开发和评估一种新的CD8向IL2剂,AB248,用于增强抗癌活性.
主要方法:
- 开发AB248,一种新型IL2变体,用于选择性结合CD8+T细胞.
- 在体外评估AB248对CD8+T细胞的影响.
- 在非人类灵长类动物体内研究,以评估选择性CD8+T细胞扩张.
- 在小鼠模型中进行的临床前疗效和耐受性研究,使用AB248代用剂与非向IL2激动剂相比.
主要成果:
- AB248显示CD8+ T细胞比自然杀伤细胞和调节性T细胞 (Tregs) 更喜欢CD8+ T细胞超过500倍.
- 在实验室中,AB248成功地重复了IL2对CD8+ T细胞的影响,并在灵长类动物中诱导了选择性的CD8+ T细胞扩张.
- 在小鼠模型中,AB248代用药与非向IL2.2相比,显示出优异的抗瘤活性和更好的耐受性.
- 疗效与瘤透的CD8+ T细胞的增加和表型增强相关,包括"更好的疗效者"群体.
结论:
- 准IL2到CD8+T细胞可以有效地将抗瘤活性与毒性脱.
- AB248通过选择性地吸引CD8+T细胞,代表了癌症治疗的有前途的治疗策略.
- 这些临床前发现支持CD8+ T细胞选择性IL2剂的临床开发,用于增强癌症免疫治疗.
更多相关视频
07:20Ex vivo Expansion of Tumor-reactive T Cells by Means of Bryostatin 1/Ionomycin and the Common Gamma Chain Cytokines Formulation
Published on: January 14, 2011
14.7K
09:15Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
3.4K
相关概念视频
Tumor Immunotherapy
523
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
523
T Cell Types and Functions
1.0K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.0K
Cytotoxic T Cells-mediated Immune Response
907
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
907
T Cell Activation and Clonal Selection
721
T cells are integral to our adaptive immune system, recognizing and effectively responding to foreign antigens. T cell activation and clonal selection are pivotal in orchestrating this immune response. This article elucidates these mechanisms, detailing the roles of cluster of differentiation (CD) markers, major histocompatibility complex (MHC) molecules, costimulatory signals, and the process of clonal selection.
Naive T cells that have not yet encountered an antigen express two primary CD...
Naive T cells that have not yet encountered an antigen express two primary CD...
721
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Cell-mediated Immune Responses
68.2K
Overview
68.2K
